Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid house dust mite immunotherapy safety study
2011-000870-79Phase 2Terminated
- Sponsor
- LETI Pharma
- Start
- Jan 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Depigoid and depigmented polymerized Dermatophagoides pteronyssinus and Dermatophagoides farinae extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), house dust mite allergy and 1 more (2 arms), sponsored by LETI Pharma. Primary endpoint: Safety. Started Jan 2012; status: terminated.
02
Drugs
Depigoiddepigmented polymerized Dermatophagoides pteronyssinus and Dermatophagoides farinae extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergyasthma
Beyond the preview
Go deeper on 2011-000870-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000870-79.